Elsevier

Life Sciences

Volume 63, Issue 12, 14 August 1998, Pages PL175-PL180
Life Sciences

Pharmacology letter Accelerated communication
Tramadol induces antidepressant-type effects in mice

https://doi.org/10.1016/S0024-3205(98)00369-5Get rights and content

Abstract

Tramadol is a clinically-effective, centrally-acting analgesic. This drug is a racemic mixture of two enantiomers, each one displaying different mechanisms: (+)tramadol displays opioid agonist properties and inhibits serotonin reuptake while (−)tramadol inhibit preferentially noradrenaline reuptake. The action of tramadol on the monoaminergic reuptake is similar to that of antidepressant drugs. Therefore, we have examined the effects of (±)tramadol, (+)tramadol and (−)tramadol in a test predictive of antidepressant activity, the forced swimming test in mice. Both (±)tramadol and its (−) enantiomer displayed a dose-dependent reduction on immobility; while the effect induced by the (+)enantiomer was not significant. Inhibition of noradrenaline synthesis, but not of serotonin synthesis, was capable of blocking the effect of (±)tramadol. The alpha-adrenoceptor antagonist phentolamine, as well as the alpha2-adrenergic antagonist yohimbine, and the beta-adrenoceptor blocker propranolol, countered the immobility-reducing action of (±)tramadol. Moreover, neither the serotoninergic blocker methysergide nor the opioid antagonist naloxone antagonized the effect of (±)tramadol. Our results show that (±)tramadol and (−)tramadol have antidepressant-like effect in mice, probably mediated by the noradrenergic system rather than the serotoninergic or opioidergic ones.

References (20)

  • M.C. Defelipe et al.

    Eur J Pharmacol

    (1989)
  • M. Hamon et al.

    Neuropharmacology

    (1987)
  • P. Tejedor-Real et al.

    Pharmacol. Biochem. Behav.

    (1995)
  • P.K. Eide et al.

    Brain Res.

    (1988)
  • R.D. Porsolt et al.

    Eur. J. Pharmacol

    (1979)
  • G. Bernatzky et al.

    Eur J Pharmacol

    (1986)
  • R.B. Raffa

    Am J Med

    (1996)
  • R.B. Raffa et al.

    J Pharmacol Exp Ther

    (1992)
  • E.E. Codd et al.

    J Pharmacol Exp Ther

    (1995)
  • R.B. Raffa et al.

    J Pharmacol Exp Ther

    (1993)
There are more references available in the full text version of this article.

Cited by (90)

  • The plausible mechanisms of tramadol for treatment of COVID-19

    2021, Medical Hypotheses
    Citation Excerpt :

    It can bind to μ-opioid receptors and inhibit norepinephrine and serotonin reuptake [20]. Through its capability to inhibit norepinephrine and serotonin reuptake, tramadol may possess antidepressant activity [18,39,40]. In this context, the antidepressant activities of tramadol may favor its indication for COVID-19 patients.

  • Panicolytic-like effect of tramadol is mediated by opioid receptors in the dorsal periaqueductal grey

    2017, Behavioural Brain Research
    Citation Excerpt :

    A previous report showed that acute and systemic administration of tramadol, at the same dose and action time we used here, produced an antidepressant-like effect in mice in the tail suspension test [28]. Furthermore, some studies using animal models of depression showed that tramadol produced an antidepressant-like effect by itself [8,9,28–30], and potentiated the antidepressant-like effect of the SNRI (serotonin and noradrenaline reuptake inhibitor), venlafaxine [31]. Currently, antidepressants are considered the drugs of choice for the treatment of PD [32], although, they have some limitations, such as delay in the onset of the therapeutic effect and worsening of initial symptoms with increased anxiety [33].

  • Cortical excitability in tramadol dependent patients: A transcranial magnetic stimulation study

    2016, Drug and Alcohol Dependence
    Citation Excerpt :

    It has a dual mechanism of action that includes both inhibition of norepinephrine and serotonin uptake and weak agonistic action on the μ-opioid receptor (Grond and Sablotzki, 2004). It is considered to be a CNS suppressant; however, some studies have indicated an activating effect of tramadol (Fox et al., 2009; Rojas-Corrales et al., 1998; Vaughan et al., 2000). Clinical studies reported tramadol to cause seizures even at recommended analgesic doses, while, experimental studies showed that convulsions only occur after high, toxic doses (Jang et al., 2010; Potschka et al., 2000; Raiger et al., 2012; Ryan and Isbister 2015).

View all citing articles on Scopus

Becaria F.P.I Univeristy of Cádiz.

View full text